Is the COP27 Focus on AEC Carbon Emissions Telling the Whole Story?

Construction sustainability continues to be an emphasis for international leaders. COP27, the UN’s gathering of more than 90 heads of state and 35,000 delegates from 190 countries, convened earlier in early November to discuss unified action against climate change and which industries need to take on a bulk of the responsibility to adjust operations and in turn reduce carbon emissions.

Chief on that list was the larger built environment, which was given extra attention considering the last year of studies have credited the AEC industry with “38%, or around 14 gigatons, of all energy-related GHG emissions each year” according to Arup and WBCSD research, as well as an increase of 5% in operational emissions between 2020 and 2021, according to Global ABC research.

Addressing emissions challenges, creating unity around 2030 climate goals, and driving toward sustainable practices is key for the AEC industry. But is this focus by COP27 a complete one, considering the various layers of the built environment that contribute to carbon emissions? Paul Doherty, AIA, IFMA Fellow and DFC Senior Fellow, recognized smart city thought leader, and founder of the digit group, tries to paint a more holistic picture of where the AEC industry needs to address its role in reducing carbon emissions.

Paul’s Thoughts on COP27

“So here’s the thing. COP27 in Egypt just ended and there was a good focus this year on the AEC community, architecture, engineering, construction community. What they’re saying is that we account for approximately 40% of all carbon emissions, both design and construction, and through demolition, that there’s a lot of embodied carbon in our processes.

That’s true, but I’m sick and tired of the finger waving that’s going on to architects, engineers, and contractors when there’s another whole side of the story, having to deal with building product manufacturers. I think if there’s a focus there, we can elicit some real change because most of these building product manufacturers are publicly traded. And what we’ve learned is that earnings reports are very important, but so are ESGs.

With the advent of smart contracts, we now have a way of having two pieces of data that are going to be put into a contractual basis that can’t be changed, that we can now track from design and construction into the actual performance of these materials over a life cycle. Exciting times.”

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More